These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 20199587)
1. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites? Jansen RS; Rosing H; Schellens JH; Beijnen JH Fundam Clin Pharmacol; 2011 Apr; 25(2):172-85. PubMed ID: 20199587 [TBL] [Abstract][Full Text] [Related]
2. Assessment of the effect of phosphorylated metabolites of anti-human immunodeficiency virus and anti-hepatitis B virus pyrimidine analogs on the behavior of human deoxycytidylate deaminase. Liou JY; Krishnan P; Hsieh CC; Dutschman GE; Cheng YC Mol Pharmacol; 2003 Jan; 63(1):105-10. PubMed ID: 12488542 [TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium. Hsu CH; Liou JY; Dutschman GE; Cheng YC Mol Pharmacol; 2005 Mar; 67(3):806-14. PubMed ID: 15550676 [TBL] [Abstract][Full Text] [Related]
4. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies. Mekras JA; Boothman DA; Perez LM; Greer S Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164 [TBL] [Abstract][Full Text] [Related]
5. Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase. Momparler RL; Rossi M; Bouchard J; Vaccaro C; Momparler LF; Bartolucci S Mol Pharmacol; 1984 May; 25(3):436-40. PubMed ID: 6203026 [TBL] [Abstract][Full Text] [Related]
6. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755. Boothman DA; Briggle TV; Greer S Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761 [TBL] [Abstract][Full Text] [Related]
7. Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs. Liou JY; Lai HR; Hsu CH; Chang WL; Hsieh MJ; Huang YC; Cheng YC Biochem Pharmacol; 2010 Feb; 79(3):381-8. PubMed ID: 19765547 [TBL] [Abstract][Full Text] [Related]
8. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. Mekras JA; Boothman DA; Greer SB Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216 [TBL] [Abstract][Full Text] [Related]
9. Incorporation of 5-substituted analogs of deoxycytidine into DNA of herpes simplex virus-infected or - transformed cells without deamination to the thymidine analog. Fox L; Dobersen MJ; Greer S Antimicrob Agents Chemother; 1983 Mar; 23(3):465-76. PubMed ID: 6303214 [TBL] [Abstract][Full Text] [Related]
10. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Heinemann V; Plunkett W Biochem Pharmacol; 1989 Nov; 38(22):4115-21. PubMed ID: 2688654 [TBL] [Abstract][Full Text] [Related]
11. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts. Snyder RD; Malick NC Mol Pharmacol; 1985 Dec; 28(6):574-80. PubMed ID: 4079913 [TBL] [Abstract][Full Text] [Related]
12. Crystal structures of Streptococcus mutans 2'-deoxycytidylate deaminase and its complex with substrate analog and allosteric regulator dCTP x Mg2+. Hou HF; Liang YH; Li LF; Su XD; Dong YH J Mol Biol; 2008 Mar; 377(1):220-31. PubMed ID: 18255096 [TBL] [Abstract][Full Text] [Related]
13. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082 [TBL] [Abstract][Full Text] [Related]
14. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Xu YZ; Plunkett W Biochem Pharmacol; 1992 Nov; 44(9):1819-27. PubMed ID: 1449536 [TBL] [Abstract][Full Text] [Related]
15. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells. Jekunen A; Vilpo JA J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484 [TBL] [Abstract][Full Text] [Related]
16. 2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Balzarini J; Cooney DA; Dalal M; Kang GJ; Cupp JE; DeClercq E; Broder S; Johns DG Mol Pharmacol; 1987 Dec; 32(6):798-806. PubMed ID: 2826994 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702 [TBL] [Abstract][Full Text] [Related]
18. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Boothman DA; Briggle TV; Greer S Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263 [TBL] [Abstract][Full Text] [Related]
19. Interaction of the high-affinity inhibitor tetrahydro-dUMP with the allosteric enzyme deoxycytidylate aminohydrolase. Nucci R; Febbraio F; Piccialli G; de Napoli L; Vaccaro C; Rossi M; Whitehead EP Arch Biochem Biophys; 1994 Apr; 310(1):49-53. PubMed ID: 8161220 [TBL] [Abstract][Full Text] [Related]
20. Human deoxycytidylate deaminase. Substrate and regulator specificities and their chemotherapeutic implications. Mancini WR; Cheng YC Mol Pharmacol; 1983 Jan; 23(1):159-64. PubMed ID: 6306421 [No Abstract] [Full Text] [Related] [Next] [New Search]